Search results
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades' - AbbVie...
Benzinga· 7 hours agoAbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters via AOL· 10 hours agoAbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 6 hours agoAbbVie has also submitted an application to the FDA, seeking approval for Skyrizi for the UC...
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges...
Benzinga· 6 hours agoAbbVie Inc’s ABBV top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year ...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
Zacks· 5 days agoFree Report) ending at $160.19, denoting a -0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.11% gain on the day. In that same time, the Medical sector gained 2.86% ...
AbbVie (ABBV) Could Be a Great Choice
Zacks· 5 days agoWhile cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is the distribution of a company's earnings paid out ...
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
Pharmaceutical Technology via Yahoo Finance· 2 days agoIn May 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use granted ...
AbbVie (ABBV) Soars 3.2%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance· 5 days agoAbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than...
CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation...
Benzinga· 6 days agoNEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) and AbbVie, Inc. If you invested in